DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy — Stella

Home/Fuchs Endothelial Corneal Dystrophy/

View on ClinicalTrials.gov

Recruiting

Back to Fuchs Endothelial Corneal Dystrophy trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

DTX-168-201 Study Site, Indianapolis, Indiana

DTX-168-201 Study Site, Grand Rapids, Michigan

Key details

Phase

Safety & dosing

Sponsor

Design Therapeutics, Inc.

Enrollment target

~28 participants

Started

July 2025

Primary completion

September 2026

Age range

30 Years and older

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.